egg-nutrition-beyond-cvd

Slice 8 — “egg nutrition beyond CVD” (searcher 1b, non-forking). Everything about egg health outside the CVD/diabetes/lipid/TMAO axis: satiety/weight, choline as a beneficial nutrient, lutein/eye health, protein/muscle, allergy/early introduction, and Salmonella. Budget: write 10, read ~20. Wrote exactly 10.

Satiety & weight/body-composition

1. S-3 - Vander Wal 2008 - Egg breakfast enhances weight loss.md — 8-week RCT, egg-vs-bagel breakfast on a calorie-deficit diet, 65% greater weight loss and 83% greater waist-circumference reduction in the egg arm. Best-first because it’s the actual weight/body-composition outcome (not just acute satiety), egg-industry funded (disclosed).
2. S-2 - Vander Wal 2005 - Short-term effect of eggs on satiety in overweight and obese subjects.md — the same group’s earlier single-meal crossover (egg vs bagel breakfast) showing greater satiety and lower 36h energy intake; the mechanistic precursor to S-3.

Choline as a beneficial essential nutrient

3. S-5 - Caudill 2018 - Maternal choline supplementation improves infant information processing speed.md — RCT, third-trimester maternal choline dose (480 vs 930 mg/d) causally speeds infant reaction time through 13 months. Best-first: it’s a controlled-feeding RCT with a hard-ish cognitive-processing outcome in the population (pregnancy/infancy) where choline stakes are highest.
4. S-7 - Zeisel 1991 - Choline, an essential nutrient for humans.md — foundational human depletion study: 3 weeks choline-free diet in healthy men produces measurable liver dysfunction, reversible on repletion. Covers essentiality + the NAFLD/liver-relevance thread in one primary; 643 citations, clearly the anchor paper of this literature.

Lutein/zeaxanthin & eye health

5. S-10 - Vishwanathan 2009 - Egg yolks increase macular pigment in statin users with low baseline pigment.md — RCT, 2 then 4 egg yolks/day for 5 weeks each raises serum lutein/zeaxanthin and macular pigment optical density (MPOD, an AMD-risk biomarker) in older statin users, up to ~50% MPOD increase at low baseline. Chosen over the pure-bioavailability papers (Chung 2004, Handelman) because it reaches an eye-health biomarker, not just serum carotenoid levels.

High-quality protein & muscle

6. S-12 - van Vliet 2017 - Whole eggs versus egg whites and postexercise muscle protein synthesis.md — RCT with amino-acid tracer infusion: whole egg produces ~40% greater postexercise myofibrillar protein synthesis than an isonitrogenous egg-white comparator in young resistance-trained men, implicating yolk-specific nutrients beyond protein/leucine content alone.

Egg allergy & early introduction

7. S-15 - Natsume 2017 - PETIT trial- two-step egg introduction prevents egg allergy in high-risk infants.md — RCT (Japan), stepwise heated-egg introduction + eczema treatment vs. placebo in high-risk infants: egg allergy at 1 year 8% vs. 38%, the largest and cleanest effect size in this trial family, without the excess-reaction problem that truncated the STAR trial.
8. S-18 - Eggesbo 2001 - Population-based prevalence of egg allergy in young children.md — Norwegian birth-cohort, objectively-confirmed point prevalence of egg allergy 1.6% at 2.5 years (parental report alone over-estimates ~1.6x); the base-rate harm figure the introduction RCTs are trying to move.

Foodborne / Salmonella risk

9. S-20 - St Louis 1988 - Emergence of grade A eggs as a major source of Salmonella enteritidis infections.md — CDC surveillance study establishing intact (not just cracked/dirty) Grade A eggs as a major, internally-contaminated (trans-ovarian) Salmonella Enteritidis vehicle; 77% of outbreaks with an identified food vehicle traced to eggs, 1985-87 Northeast US. The foundational epidemiological primary for this thread.
10. S-24 - USDA-FSIS Salmonella Enteritidis risk assessment for shell eggs and egg products.md — the quantitative farm-to-table risk-assessment model behind US egg-safety rulemaking: baseline ~661,633 SE illnesses/year from ~2.3M contaminated eggs (of 46.8B produced), with storage temperature/duration as the dominant risk driver (~30-47x risk swing). Note in the node itself: full PDF fetch was blocked (403) by the host, so its numbers were sourced from secondary web summaries of the executive summary — step 2/3 should re-open the primary PDF directly before leaning on the exact figures.

search_scope

Web search (general search engine, not a dedicated bibliographic index — no Google Scholar/PubMed/Semantic Scholar UI access in this environment) for each named anchor in the searcher brief (Vander Wal 2005/2008, Ratliff 2010, Fallaize 2013; Caudill 2018, Zeisel choline-essentiality; Handelman, Chung 2004, Vishwanathan/Kelly egg-lutein trials; van Vliet 2017; LEAP/EAT/PETIT/STAR egg-allergy trials, egg-allergy population studies; St Louis 1988, USDA-FSIS/EFSA Salmonella reports). Confirmed metadata (author list, venue, date, DOI/PMID) via PubMed/PMC/journal pages through WebFetch, and citation counts via the Semantic Scholar Graph API (queried directly by DOI/PMID; several calls were rate-limited — see exclusions/gaps). No formal reference-list snowballing was done (no PDF full-text access to most primaries in this environment); coverage instead relied on multiple independent web searches per thread plus the named anchors already supplied in the brief, cross-checked against secondary sources (news/summary sites, egginfo.co.uk, medicalxpress) only for orientation, never as the node’s own citation basis.

exclusions

1. Ratliff 2010 (Nutrition Research) — egg-breakfast acute satiety/ghrelin/glucose in men — not minted; redundant with Vander Wal 2005/2008 (same direction, same paradigm), noted here as a secondary confirmatory primary if step 2 wants more satiety depth.
2. Fallaize 2013 (three-breakfast crossover, egg/toast vs. cereal vs. croissant) — not minted; same satiety direction as Vander Wal, budget prioritized the weight-loss (not just single-meal) outcome instead.
3. Chung 2004 (J Nutr) and Handelman (bioavailability reviews/studies) — lutein bioavailability-only papers (serum lutein, not an eye-health endpoint); not minted, used to help choose Vishwanathan 2009 as the primary that reaches an actual retinal biomarker. Kelly et al. buttermilk-drink MPOD trial — a plausible alternate/duplicate primary to S-10, not minted (same design family, egg-yolk-based beverage rather than whole yolks).
4. Wallace & Fulgoni 2016 (NHANES choline-intake assessment, ~10.8% of US population meeting the choline AI) — a strong candidate for “choline adequacy/AI intake data” but not minted under this slice’s 10-note budget; recorded here as a gap (see below) rather than found_via since it wasn’t superseded by anything I did mint — step 2/3 may want to pull it in separately.
5. Perkin 2016 NEJM (EAT study egg arm) and Palmer 2013 JACI (STAR trial) — both named anchors for the allergy/early-introduction thread; not minted because PETIT (S-15) gives the cleanest, largest, most-replicated effect and the budget for this thread was 2 notes (intervention + epidemiology). EAT’s ITT result was null (only per-protocol significant) and STAR was stopped early for excess reactions — both are informative contrast cases step 2/3 should know about even though I didn’t mint them; flagging so they aren’t silently lost.
6. Semantic Scholar Graph API calls for St Louis 1988 (JAMA, PMID 3279240) were repeatedly rate-limited (HTTP 429) after the WebSearch tool budget for this session was also exhausted; citation_count on S-20 is left unknown rather than guessed.

Slice paragraph

This slice is intentionally the “everything else” bucket the FLF framing’s “what else should we be paying attention to” clause asks for, and it is genuinely mixed-valence: 6 of the 10 primaries (satiety x2, choline x2, lutein, protein) are benefit-side, and 2 (Salmonella x2) are unambiguous non-CVD harm, with allergy (2) split — PETIT is itself a benefit (prevention works) but sits on top of a real background harm (Eggesbø’s prevalence figure). No single sub-thread got more than 2 notes, in line with “mostly one primary each, breadth over depth.” The clearest gap is protein/muscle: the brief asked specifically for an elderly/sarcopenia population, but van Vliet 2017 (like most of this specific mechanistic literature) was run in young trained men — I could not find a whole-egg-vs-alternative-protein MPS or lean-mass RCT specifically in elderly/sarcopenic subjects within budget; this is a real gap, not a considered exclusion, and worth a targeted top-up search if step 2 flags it. Environment note: this searcher had no PubMed/Google-Scholar UI, no PDF full-text access, and a shared, exhaustible WebSearch quota (hit its cap late in this run) plus a rate-limited Semantic Scholar API — all metadata above was cross-checked at least once via WebFetch on a primary-source page (PubMed/PMC/journal site) rather than taken from a single search snippet, except where explicitly flagged (S-24’s numbers, sourced secondarily because the host blocked direct PDF fetch).